Bezafibrate 200 mg

DRUG2 trials

Sponsors

Intercept Pharmaceuticals

Conditions

Primary Biliary Cholangitis

Phase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

TerminatedNCT04594694

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2019-10-02End: 2025-10-14Updated: 2025-11-17

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

CompletedNCT05239468

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2022-03-21End: 2025-09-01Updated: 2025-09-25